<i>miR-29</i> modulates CD40 signaling in chronic lymphocytic leukemia by targeting TRAF4: an axis affected by BCR inhibitors
Sonali Sharma(Central European Institute of Technology), Marek Mráz(Central European Institute of Technology), Stacey M. Fernandes(Dana-Farber Cancer Institute), Laura Z. Rassenti(University of California San Diego), Václav Šeda(Central European Institute of Technology), Jennifer R. Brown(Dana-Farber Cancer Institute), Daniel Filip(Central European Institute of Technology), Andrea Janíková(Masaryk University), Thomas J. Kipps(University of California San Diego), Michael Doubek(Central European Institute of Technology), Gabriela Mladonická Pavlasová(Central European Institute of Technology), Jiřı́ Mayer(Masaryk University), Leoš Křen(University Hospital Brno), Marek Borský(Masaryk University), Matthew S. Davids(Dana-Farber Cancer Institute), Medhat Shehata(Comprehensive Cancer Center Vienna), Laura Ondrišová(Central European Institute of Technology), Šárka Pospı́šilová(Central European Institute of Technology), Květoslava Lišková(Masaryk University), Veronika Šandová(Central European Institute of Technology), Jan Oppelt(Central European Institute of Technology), Kateřina Amruz Černá(Central European Institute of Technology), Eva Vojáčková(Central European Institute of Technology), Lenka Košťálová(Central European Institute of Technology), Ulrich Jaeger(Medical University of Vienna), Pedro Faria Zeni(Central European Institute of Technology)
Cited by 63
Related Papers
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
|Molecular Cancer|2023|1.9k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k
iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL
|Blood|2018|1.7k
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2014|1.7k